ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CDTX Cidara Therapeutics Inc

12.51
-0.17 (-1.34%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cidara Therapeutics Inc NASDAQ:CDTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.17 -1.34% 12.51 10.92 32.00 13.1999 11.75 11.75 54,051 05:00:14

The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair

30/01/2018 3:18pm

PR Newswire (US)


Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cidara Therapeutics Charts.

WASHINGTON, Jan. 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today that Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice Chair, joining Vice Chair Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) and Chairman Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, Inc. (NASDAQ: CDTX).

"On behalf of AWG, I would like to welcome Dr. Dunne as Vice Chair," said Dr. Jeffrey Stein, AWG Chairman. "As an infectious disease physician and long-standing member of AWG, the Board of Directors is confident Dr. Dunne will contribute valuable insight in the position as Vice Chair."

"I'm delighted to serve as Vice Chair of our coalition of infectious disease companies committed to advancing innovations in antimicrobial drug and diagnostic device development," said Dr. Michael Dunne. "I look forward to the opportunity to engage with the leadership of AWG to promote legislation and regulatory policies that address barriers that hinder an emerging company's ability to develop new treatment options for serious, and life-threatening diseases."

All pharmaceutical and biotechnology companies developing new antimicrobial therapeutics and rapid diagnostic devices are eligible for consideration of membership in AWG. If you are interested in learning more about becoming a member of AWG, please contact us here.

About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of seventeen antimicrobials and diagnostic device companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc., T2 Biosystems Inc., Theravance Biopharma U.S. Inc., VPS-3 Inc., Vical Incorporated, and Zavante Therapeutics Inc.

For more information, visit: www.antimicrobialsworkinggroup.org

About The Conafay Group
The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.

For more information, visit: www.conafaygroup.com

 

Cision View original content:http://www.prnewswire.com/news-releases/the-antimicrobials-working-group-announces-the-appointment-of-dr-michael-dunne-as-vice-chair-300589297.html

SOURCE Antimicrobials Working Group (AWG)

Copyright 2018 PR Newswire

1 Year Cidara Therapeutics Chart

1 Year Cidara Therapeutics Chart

1 Month Cidara Therapeutics Chart

1 Month Cidara Therapeutics Chart

Your Recent History

Delayed Upgrade Clock